HKTDC Hong Kong Watch & Clock Competition promotes innovation ACN Newswire

HKTDC Hong Kong Watch & Clock Competition promotes innovation

HONG KONG, Sep 6, 2022 - (ACN Newswire via SEAPRWire.com) - The 41st HKTDC Hong Kong Watch & Clock Fair and 10th Salon de TE, organised by the Hong Kong Trade Development Council (HKTDC), Hong Kong Watch Manufacturers Association Ltd and The Federation of Hong Kong Watch Trades and Industries Ltd, will run from 7 to 11 September at the Hong Kong Convention and Exhibition Centre (HKCEC). The 39th Hong Kong Watch & Clock Competition, is hosted by the HKTDC Hong Kong Watch & Clock Fair 2022 Organising Committee, and co-organised by the Hong Kong Watch Manufacturers Association Ltd and The Federation of Hong Kong Watch Trades & Industries Ltd. Competition results have been officially announced and all winning and finalist entries will be on display during the Watch & Clock Fair.Open Group champion of the 39th Hong Kong Watch & Clock Design Competition: "Geisha"The HKTDC, the Federation of Hong Kong Watch Trades & Industries Ltd and the Hong Kong Watch Manufacturers Association Ltd co-organised this year's Hong Kong International Watch Forum, inviting watch association representatives from Mainland China, France, Germany, Hong Kong, Japan and Switzerland to discuss trade performance in their respective regions.In advance of the fairs, the Hong Kong International Watch Forum was held yesterday (5 September) to help industry professionals grasp global trends and prospects. The forum invited watch association representatives from Mainland China, France, Germany, Hong Kong, Japan and Switzerland to discuss trade performance in their respective regions and offer perspectives on the global watchmaking industry.Hong Kong Watch & Clock Competition uncovers design talentsThe 39th Hong Kong Watch & Clock Competition aims to promote innovation in the local watch and clock industry, at the same time revealing local design talents and injecting new impetus into the industry. This year's competition was again divided into the Open Group and the Student Group, with the respective themes of "Night" and "Race Against Time". Nearly 70 high-quality entries were received, with a judging panel of nine industry leaders and celebrities selecting winners.The Open Group champion was won by the Ballerina Watch Company Limited design "Geisha". The charcoal-coloured watch case features a sake glass and a geisha silhouette dial face handmade in sterling silver. Time is subtly shown in the middle of the geisha's fan, while traditional kimono patterns are printed on the back of the strap to echo the geisha design on the surface. First runner-up in the Open Group was clinched by Tam Kwok-tung for "StarTrack". Set against a backdrop of the night sky, the design features an "8" shape with stars telling the time at the top and an automatic winding rotor at the bottom. It is as if the complex mechanical movement of the rotor gives the stars a gravitational pull to guide it to tell the time. Meanwhile, the second runner-up spot went to Heromex Holdings Company Limited for its design "NOCTUS". Featuring a little field mouse as the hour hand and an owl as the minute hand, the two characters tell the fable of the forest as they revolve around the dial.In the Student Group, Yip Tsz-yan of SHAPE (DILWL) was declared champion for her design "Present". Taking inspiration from a camera lens, the watch features a case with a mechanical design that can be opened and closed manually. Its strap is designed without a clasp and cleverly uses the elasticity of the metal to open and shut. First runner-up was Cheung Ning-yi of the Hong Kong Design Institute, whose design empowers the wearer to be the goddess in charge of her own time. Lee Kwan-ho of the Hong Kong Polytechnic University clinched the second runner-up spot with "The Moment", whose design embodies the message: "The preciousness of time is that people learn to cherish it".Visitors will be able to appreciate the winners' works and vote for the "Most Popular Award". The awards presentation ceremony will be held on Saturday 10 September, 4pm at the Time Chamber in Hall 1 of the Hong Kong Convention and Exhibition Centre (HKCEC).Forum offers perspectives on the global watchmaking industryRepresentatives from various regions share details of the trade performance in their respective regions and offer perspectives on the global watchmaking industry at the Hong Kong International Watch Forum was held yesterday (5 September) to help industry professionals grasp the latest global trends and prospects.Mainland China watch market trends higher since JuneCiting statistics from 270 watch and clock enterprises in Mainland China, Zhang Hong-guang, Director General of the China Horologe Association, said the industry's cumulative operating income in the first half of this year reached Rmb13.73 billion - a slight drop of 2.7% from the previous year. Operating income in April fell 13.1% year on year as a result of COVID-19 pandemic controls. During the first half, the industry recorded a loss of Rmb170 million, a decrease of 31.2% compared to the same period last year. The industry's profits dropped 15.2% to Rmb450 million in the first half of 2022.Mr Zhang said the mainland's cumulative watch and clock exports showed an overall upward trend between January and July. Cumulative exports reached US$2.68 billion, up 12.1% year on year. With the exception of February, exports showed a month-on-month increase, indicating a positive outlook overall. Imports, however, showed a general downward trend. From January to July, cumulative imports were down 24.8% on the same period last year at US$2.51 billion.He concluded that the performance of the mainland's watch and clock industry remained steady in comparison with last year, with a 22% reduction in losses and a slight decrease in revenue from the main businesses. With the consumer market recovering gradually since June, the industry's productivity and sales have shown a significant improvement, with an uptick in profitability, indicating the market is picking up.Japanese watch exports boosted by demand for high-priced mechanical watchesThe watch and clock industry in Japan is primarily driven by exports, particularly of watches. In the first half of this year, the industry saw a remarkable recovery, with growth almost returning to the 2019 pre-pandemic level. Citing statistics from association members, Mari Yamazaki, General Manager of the Japan Clock and Watch Association, said Japan's domestic watch sales volume fell 3% year on year with the biggest decline in the digital quartz watches and mechanical watches.The results were mainly attributable to decreased demand from tourists as a result of Japan's stringent anti-pandemic entry restrictions. Despite the drop in sales quantity, overall sales rose 2% year on year as watch values rose. Sales of high-priced mechanical watches grew 34% year on year due to increased demand. Ms Yamazaki added that as various countries gradually eased their anti-pandemic restrictions, Japan's watch exports rose 13% in quantity and 20% in value year on year, fuelled primarily by the North American market. Thanks to the satisfactory export performance, Japan's overall watch sales increased 12% in value and 13% in quantity year on year in the first half of 2022.In terms of clocks, while the domestic sales volume and value in Japan fell nearly 10% year on year during this period, global exports rose 8% in quantity and a remarkable 68% in value thanks to the economic recovery in overseas markets. Ms Yamazaki said overall clock quantity sold fell by 9% year on year but total sales increased 1% to 8.5 billion yen, with a downward year on year trend. This was due to weak domestic consumption in Japan.Swiss watch exports surpass 11bn Swiss francs for first timeGlobal Swiss watch exports enjoyed a strong performance in the first half, led by precious-metal or steel mechanical watches. According to Thierry Dubois, Managing Director, APAC, Federation of the Swiss Watch Industry FH, the downturn driven by macroeconomic and geopolitical issues as well as the pandemic had a limited impact on Switzerland's watch sector.In the first six months, Swiss watch exports grew 11.9% year on year to more than 11 billion Swiss francs (US$11.23 billion). The export quantity rose to 7.2 million units, up 3% year on year. Quartz watches recorded the most noticeable growth, followed by mechanical watches, with the performance of watches priced at more than 3,000 Swiss francs showing the greatest strength. Mr Dubois noted that although Swiss watch exports had previously been sluggish, the performance had improved since last year.He added that Asia accounted for nearly half (49%) of Swiss watch exports in the first half of this year, with Europe (30%) and the United States (19%) being the second- and third-largest markets respectively. Most markets showed clear growth in demand. The US (+31.4%) led the way, followed by France (+36.5%), the United Kingdom (+31.8%), Germany (+25.4%), Singapore (21.4%) and Japan (+19.5%). However, the market in Mainland China was significantly disrupted by anti-pandemic measures in April and May, resulting in a drop in sales (-26.3%) during the first half of this year. Hong Kong also recorded a drop (-11.5%) during this period.Mr Dubois concluded that prospects for the Swiss watch industry remained optimistic this year, despite uncertainties in macroeconomic prospects. He predicted watches will continue to benefit from sustained demand and the appeal of luxury goods. However, challenges such as raw-material supply, rising energy and transport costs, and manpower shortages will have an impact on turnover.The Hong Kong International Watch Forum was held as a webinar on 5 September. A recording of the full event is available on the fair websites.Insiders reveal insights on trends and prospects at Asian Watch ConferenceThe annual Asian Watch Conference will be held tomorrow (8 September) under the theme "Watches Beyond - Transformation and Reinvention". Experts including Anna Dai, Research Analyst at Euromonitor International, and Zi-Yong Ho, Co-head of Sales, International Specialist, Director, Watches at Phillips, have been invited to discuss a range of issues, including the latest development trends in the watch market, business opportunities in blockchain, transactions with blockchain technology and non-fungible tokens (NFTs). Trade professionals interested in joining the conference can register here. https://www.hktdc.com/event/hkwatchfair/enIndustry participants are also invited to join a number of seminars and forums that will bring them up to date on market trends and prospects. The "Cross-Border eCommerce: How to Win in Southeast Asia" talk on 9 September will feature Chois Choi, Strategy Consultant, Source Network Media Group Limited, who will look at how cross-border e-commerce in Southeast Asia has created unprecedented business growth through short video platforms, and how this trend can help the watch industry increase brand popularity and boost sales.Opportunity to assess global market trendsThe 41st HKTDC Hong Kong Watch & Clock Fair and 10th Salon de TE open tomorrow. The physical fairs run from 7 to 11 September at the Hong Kong Convention and Exhibition Centre (HKCEC), while the online exhibition will run from 7 to 18 September, helping global watch traders explore business opportunities both in person and online. The physical fairs at the HKCEC will be open to industry buyers and also to the general public, offering watch lovers the opportunity to shop for precious timepieces.Fair websites- Hong Kong Watch & Clock Fair: https://hkwatchfair.hktdc.com- Salon de TE: https://hkwatchfair.hktdc.com/te- Electronic coupons download: https://bit.ly/3PPLUOM- Photo download: https://bit.ly/3D0dNANAbout HKTDC The Hong Kong Trade Development Council (HKTDC) is a statutory body established in 1966 to promote, assist and develop Hong Kong's trade. With 50 offices globally, including 13 in Mainland China, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly small and medium-sized enterprises (SMEs), in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via research reports and digital news channels. For more information, please visit: www.hktdc.com/aboutus. Follow us on Twitter @hktdc and LinkedInMedia enquiriesPlease contact the HKTDC's Communications & Public Affairs Department:Kate Chan, Tel: +852 2584 4239, Email: kate.hy.chan@hktdc.orgClementine Cheung, Tel: +852 2584 4514, Email: clementine.hm.cheung@hktdc.org Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More
Oculis announces publication and presentation of Phase 2 data showing topical OCS-01 improves macular thickness and visual acuity in patients with diabetic macular edema ACN Newswire

Oculis announces publication and presentation of Phase 2 data showing topical OCS-01 improves macular thickness and visual acuity in patients with diabetic macular edema

LAUSANNE, Switzerland, Sep 6, 2022 - (ACN Newswire via SEAPRWire.com) - Oculis S.A., ('Oculis') a global ophthalmology company developing life-changing treatments to save sight and improve eye care with breakthrough innovations, announces that the Phase 2 DX-211, a randomized, double blinded, multi-center and vehicle controlled clinical trial assessing the safety and efficacy of topical OCS-01 in patients with Diabetic Macular Edema (DME) (NCT05343156) has been published by the Acta Ophthalmologica journal. The publication is accessible on the National Institutes of Health (NIH) website here ( https://pubmed.ncbi.nlm.nih.gov/35848336/ ). In addition, a new subgroup analysis of this study was also recently presented by Pr R. Tadayoni at the 22nd EURETINA Congress on 2nd September in Hamburg, Germany.-- Positive Phase 2 data, published in journal ACTA, provides the first proof-of-concept for a topical drug effect in diabetic macular edema (DME) -- Dataset shows that OCS-01 eye drops were more effective than vehicle in reducing central macular thickness and improving visual acuity in patients with DME as per the pre-defined criteria for statistical superiority in the study protocol-- Subgroup analysis, presented by Pr Ramin Tadayoni at EURETINA, suggests even greater improvement in patients with lower baseline visual acuity-- If approved, OCS-01 has the potential to provide a new and potentially the FIRST non-invasive eye drop option for DME patientsThe dataset published shows OCS-01 to be superior to vehicle in the primary efficacy analysis of BCVA change from baseline with a between group difference of +1.58 ETDRS letters at the pre-specified significance level of 0.15. Mean CMT showed a statistically significant greater decrease from baseline in the OCS-01 group compared to vehicle at all post-baseline time points up to and including Week 12 (-54micrometer OCS-01 vs. -17micrometer vehicle) and reversed towards baseline when treatment stopped at 12 weeks, demonstrating the pharmacological effect of OCS-01 on retinal edema. OCS-01 was well tolerated and no significant or unanticipated ocular adverse events were observed.Subgroup analysis in patients with BCVA baseline is less than or equal to 65 letters, presented at EURETINA 2022, showed greater improvements in both CMT (-77.4micrometer OCS-01 vs. -23.1micrometer vehicle) and BCVA (+2.9 ETDRS letters in OCS-01 vs vehicle) at week 12.Approximately 37 million people are affected by DME worldwide, representing around 7% of the large and growing diabetes patient population. DME is the build-up of fluid (edema) in the macula (the macula is important for the sharp, straight-ahead vision that is used for reading, recognizing faces, and driving). DME is the most common cause of vision loss among people with diabetic retinopathy and a leading cause of new cases of blindness in US adults. Although treatment options currently exist, all of them are invasive (injections or implants) and represent a significant burden for patients and caregivers. OCS-01 is a novel, high concentration, preservative free, topical formulation of dexamethasone that has the potential to be the first topical eye drop and non-invasive treatment for DME. OCS-01 opens up the possibility of treating DME patients at all stages of disease with an eye drop. In addition, OCS-01 could increase the accessibility to treatment of those patients without easy access to specialists; together, this could significantly reduce the burden to the health care system and improve patient outcomes and quality of life.OCS-01 is currently under investigation for the treatment of DME in the ongoing Phase 3 DIAMOND trial to confirm these findings in a larger patient population. Riad Sherif, M.D., CEO of Oculis, said: "We are delighted by these data from the Phase 2 DX-211 study, which further reinforce the potential of OCS-01 to provide patients with a potentially transformative treatment of DME as the first non-invasive, eye drop, option. An effective topical treatment for DME could expand the proportion of patients treated, especially those with recent onset DME, as well as provide a treatment option to general ophthalmologists prior to referral to a retina specialist and thereby, improving access to treatment. We look forward to the results of the ongoing Phase 3 DIAMOND trial as Oculis seeks to deliver life-changing treatments that can be accessed globally for the world's most prevalent ocular diseases." Pr Ramin Tadayoni, MD, PhD, Professor of Ophthalmology at Universite de Paris, said: "The development of effective topical eye drops for posterior segment disorders such as DME would offer easier, non-invasive options than those currently available, and could be widely adopted across all socioeconomic and geographic boundaries. This would allow earlier treatment in DME, reduce the burden on both patients and their caregivers with potentially less injections per year if combined with current standard of care, increase adherence and ultimately, improve outcomes worldwide. OCS-01 is the most developed and promising topical therapy for DME to date, and I look forward to its further development as a potentially transformative treatment for patients in need."About OculisOculis is a global biopharmaceutical company purposefully driven to save sight, improve eye care and address significant unmet medical needs with breakthrough innovations. Oculis's highly differentiated pipeline includes candidates for topical retinal treatments, topical biologics and disease modifying treatments. With a presence in key international markets, Oculis is poised to deliver life-changing treatments to patients worldwide. Headquartered in Lausanne, Switzerland and with operations in Europe, the U.S. and China, Oculis is led by an experienced management team with a successful track record and supported by leading international healthcare investors.For more information, please visit: www.oculis.com Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More
移卡(09923.HK)涨4.45% 多家大行给予“买入”评级 ACN Newswire

移卡(09923.HK)涨4.45% 多家大行给予“买入”评级

HONG KONG, Sep 6, 2022 - (亚太商讯 via SEAPRWire.com) - 中国领先的以支付为基础的科技平台——移卡有限公司(「移卡」或「公司」,股份代号:9923.HK)涨4.45%,报收于17.86港元/股。近五个交易日累计涨约30%。日前,移卡公布2022年中期业绩:截至2022年6月30日止6个月,公司收入为人民币16.42亿元,同比增长17.07%;毛利为人民币5.29亿元,同比增长52.05%。其中,公司GPV同比增长7.4%至约人民币1.06万亿元;到店电商业务GMV及付费消费者数目于报告期内分别达到近人民币14亿元及970万,较2021年同期分别增长1,789.7%及578.9%,而于报告期内月活跃用户(MAU)超过1900万名。同时移卡也披露了股权回购消息,称根据公司股东于2022年6月24日举行的股东周年大会上通过的决议案,董事获授予一般无条件授权,可购回最多4519.03万股股份。9月5日,移卡耗资495.5万港元回购29.2万股,回购价格每股16.74-17.08港元。此举在中小科技企业中颇为少见,这也说明移卡管理层对公司未来业绩的增长极具信心。鉴于移卡亮眼的中期业绩及管理层对公司未来发展的预期,野村、CLSA分别上调移卡评级至“买入”。野村发表研究报告表示,其中期业绩稳固,收入按年增长17%,主要受支付业务及店内业务强劲增长所推动。截至今日收盘,中金、国盛、广发、中信建投等十余家机构均给予“买入”评级,移卡投资价值进一步彰显。关于移卡有限公司(股份代号:9923.HK)移卡是一家基于支付的领先科技平台,专注为商户和消费者创造价值。我们的目标是建立一个独立可扩展的商业数字化生态系统,以实现商户与消费者之间无缝、便捷及可靠的支付交易,并延展到为商家和消费者提供丰富多样的产品组合,目前包括(i)到店电商服务,为消费者提供一站式的超值本地生活服务;以及(ii)商户解决方案,帮助商户更好的管理及推动业务增长。 Copyright 2022 亚太商讯. All rights reserved. (via SEAPRWire)
More

重估中国优势 广发证券 2022 年资本论坛成功举办

EQS 新闻 via SEAPRWire.com / 2022-09-06 / 18:13 UTC+8 广发证券股份有限公司 GF Securities Co., Ltd. (HKSE:1776; SZSE:000776) 重估中国优势 广发证券 2022 年资本论坛成功举办 【香港讯,2022年9月6日】2022年8月30日至9月2日,由广发证券(000776.SZ,1776.HK)主办的“‘重估中国优势’——广发证券2022年资本论坛暨上市公司闭门交流会”在杭州成功举办。各金融机构和上市公司代表、战略客户、高净值客户、产业专家、行业资深人士等到场参会,聚焦全球环境变化和疫情影响下的中国经济形势与市场格局,探寻中国改革发展新优势。 8月30日,中国社科院学部委员、国家金融与发展实验室理事长李扬,全国政协经济委员会副主任、国务院发展研究中心原副主任刘世锦,中国社科院学部委员、世界经济与政治研究所研究员余永定,国家发改委宏观经济研究院原副院长马晓河,原南方科技大学商学院院长、讲席教授,原清华大学五道口金融学院副院长、紫光金融学讲席教授周皓,复旦大学美国研究中心副主任、台湾研究中心创始主任信强,广发证券首席经济学家郭磊博士,广发证券策略研究首席分析师戴康等嘉宾出席主旨论坛、海外论坛活动并作主题演讲,与现场嘉宾共享价值机遇及精彩纷呈的思辨之光。广发证券副总经理张威做开幕致辞。主旨论坛由广发证券发展研究中心总经理、电子首席分析师许兴军主持。 百年未有变局 读懂中国新优势 进入21世纪以来,世界也进入了百年未有之大变局时代。与过去不同的是,这一次世界变革,中国已经从被动顺势,转变为主要推动力量之一,呈现出新的发展格局和趋势。 (广发证券副总经理张威致辞) 张威在开幕致辞中表示,本次论坛围绕海内外宏观政策、大类资产配置、双碳周期&能源革命、全球变局下的半导体产业、疫后消费复苏等重要话题,从三个方面重估中国优势,挖掘新的投资机遇:一要重估中国经济优势,在全球经济增长缺乏新引擎的背景下,对中国经济高品质发展前景进行定价;二要重估中国产业优势,乘势中国产业升级浪潮,对经济结构转型的优势赛道进行定价;三要重估中国企业优势,掘金中国新时代发展机遇下的优势企业,对资本市场优质上市公司定价。 李扬表示,国内经济发展面临的压力依旧存在。未来宏观调控仍需加大力度,财政政策应当走向前台,货币政策则要“为稳定经济创造适宜的货币金融环境”。长期来看,仍然要坚持以改革开放为动力,致力于营造“让国企敢干、民企敢闯、外企敢投”的政策和制度环境,促进经济实现真正的高质量发展。 刘世锦表示,投资方面除需关注基建以外,还有其他有关消费结构升级的服务业投资。从供给侧来看,需要继续激发结构性潜能,要关注“1+3+2”结构性潜能框架,即以都市圈城市群的发展为龙头,补上基础产业效率不高、中等收入群体规模不大、基础研发能力不强这三大短板;以及通过数字经济和绿色发展赋能。 全球环境复杂 发展需要新思路 今年以来,外部地缘政治风险和全球通胀压力加大,内部疫情扰动导致局部经济受影响,对国内发展带来前所未有挑战,也为改革发展提出新的要求。 余永定指出,2022年第三季度至2023年,美国和全球的经济形势不容乐观。美国经济增速大概率会持续走低,欧洲不能排除陷入滞涨的可能性,日本经济不会有明显变化,发展中国家经济则可能加速分化。尽管外部环境恶化,中国经济在很大程度上能够隔离来自外部的不利冲击。在当前形势下,为了稳定增长,中国可以适度容忍杠杆率的提高,必要时要容忍一定程度的通胀。只要坚持“两个循环、内循环为主”的战略方针,坚持执行扩张性财政政策和货币政策,在国内外重重困难的包围下,中国经济依然能够实现“突围”并取得较好实绩。 马晓河认为,我国经济面临的压力主要表现在两个方面。一是在需求侧,表现为两降一升,即投资增长率不断下降,消费增长严重收缩,甚至出现连续负增长;二是在供给侧,表现为一稳两放缓,即农业稳,夏粮丰收,农产品供给丰裕,但制造业和服务业增长率连续下滑,两大产业出现了明显负增长。其中,既有短期因素,由国内外重大事件导致的供给冲击和需求冲击,更重要的是我国的结构性矛盾。结构性矛盾体现在需求端,就是投资与消费长期失衡,消费引领经济增长能力不足;在供给端,中低端制造业供给过剩,中高端制造业发展不足;在动力机制上,大规模复制创新难以支持经济增长再迈新台阶,但自主创新仍然不足。因此,改革与发展需要新的思路和对策。 周皓表示,美欧升息对中国的影响比较中性或者不是太大,对中国资本市场的影响不是很大。中国经济现在的挑战,是在下半年如何实现更快增长。在疫情压力逐步缓和、防疫政策进一步精准化之后,中国经济的毛细血管将得到改善,经济增长出现反弹预期。 信强认为,美国不断加剧的对华战略打压和围堵,与新冠疫情的蔓延以及俄乌冲突延续相叠加,不仅为全球战略格局的演变注入了巨大的不确定性,而且对中国的外交战略和安全环境产生了重要影响。随着美国对华战略定位、战略目标、战略思维和战略手段的变化,未来随着中美战略的博弈也将持续展开,进而对中美关系未来的发展和演变产生重大影响。 修复预期 市场或迎新增长 今年以来,面对复杂严峻的国际环境、多点散发的国内疫情,资本市场呈现震荡格局。 周皓强调,中国是个大的内生性经济,疫情对经济的影响进一步减小之后,政府再做出正确的预期引导,市场主体的信心将得到极大的提振,其融资需求疲软的状况也将得到改善。 郭磊博士在题为“阳关三叠:三个时间维度看当前宏观面”的主题演讲中指出,7月经济放缓导致宏观面预期被打破,8月高频数据已基本企稳,本轮经济放缓带给股债两端的影响可能已大致反映完毕,9月随疫情、气温等因素高点过去,以及政策继续升温,宏观预期预计会有所修复。疫情防控常态化期间消费的天花板效应决定GDP的上限。短期增长的天花板效应和政策的偏宽来“资产荒”逻辑。逻辑上未来有三种可能打破目前状态,一是海外衰退;二是消费上限打开;三是地产形成对冲。三条线索目前尚未有端倪出现。往中期看,GDP增长目标下,投资率重新打平将是一个关键线索。从2035年GDP翻番目标倒推,则GDP年均复合增长率要在4.7%左右,其中第一个五年需要在5%以上,对应固定资产投资要在5%左右,这需要基建的现代化基础设施体系、地产的新发展模式、制造业的产业基础高级化等框架的搭建。从长期看,名义增长是股债定价的定价锚。无论是股票还是债券,其长期中枢都呈现出符合名义GDP定价的有效性。 戴康表示,全球大类资产三季度演绎“紧缩+衰退”共振,四季度“衰退交易”将逐渐占据主导,大类资产或呈现美债利率高位运行后下行,大宗商品震荡分化,美股受盈利拖累下行。A股大势研判演绎“此消彼长,水到渠成”。此消(美国衰退),彼长(中国复苏),大概率演绎“美国衰退得快+中国复苏得慢”,贴现率驱动A股震荡上行,成长占优。今年小盘占优具备走出中等级别行情的潜质,不过随着相对估值修复至均值、信用利差历史低位之后,应留意地产基建信用预期变化带来的短期切换。 戴康建议行业配置布局“资产重估,中国优势”。从“资产重估”来看,一方面压制性政策转向边际宽松的地产链将迎来重估,如地产、消费建材和家电等,另一方面“供需缺口”支撑的资源品迎来估值体系重塑,如煤炭、有色小金属等。从“中国优势”来看,一方面中国的消费优势,将依托于疫后内需市场的复苏实现供需修复,如食品饮料、批零社服,另一方面中国的制造业优势,将继续享受全球份额的提升及产业链的创新升级,如风电零部件、光伏组件、智能汽车;主题投资关注能源安全和国企改革。 对于港股后续走势,戴康指出,当前美国存量流动性极度充裕,美联储加息周期,基本面改善亦能驱动港股上行。中美经济周期错位,中期港股上行趋势更为确定,待年底中国经济增长预期回升和美联储收紧放缓均兑现,为港股趋势上行提供积极催化剂。行业配置上关注“兼顾反转与确定性”三条主线,一是具有确定性的高股息策略;二是趋势反转,如供需梗阻进一步疏通的地产,疫后修复的餐饮供应链、啤酒,国潮的黄金珠宝、体育、化妆品,以及政策反转的平台经济、创新药等;三是追随景气,如具有中国制造优势的新能源车等。 除主旨论坛和海外论坛外,广发证券还精心筹画了14场产业分论坛,交流内容覆盖新能源产业链、半导体国产替代、消费复苏与品牌崛起、消费医疗、大类资产配置等市场关心热点,邀请约500家优质上市公司做闭门交流,共论产业发展趋势和投资机遇,推动产业与资本之间的高效沟通,发掘未来投资机遇。 2022-09-06 此新闻稿由EQS Group via SEAPRWire.com转载。本公告内容由发行人全权负责。原文链接: http://www.todayir.com/sc/index.php
More
重估中国优势 广发证券2022年资本论坛成功举办 ACN Newswire

重估中国优势 广发证券2022年资本论坛成功举办

HONG KONG, Sep 6, 2022 - (亚太商讯 via SEAPRWire.com) - 2022年8月30日至9月2日,由广发证券(000776.SZ,1776.HK)主办的“‘重估中国优势’——广发证券2022年资本论坛暨上市公司闭门交流会”在杭州成功举办。各金融机构和上市公司代表、战略客户、高净值客户、产业专家、行业资深人士等到场参会,聚焦全球环境变化和疫情影响下的中国经济形势与市场格局,探寻中国改革发展新优势。(广发证券副总经理张威致辞)(李扬作主题演讲)(刘世锦作主题演讲)(余永定作主题演讲)(马晓河作主题演讲)(周皓作主题演讲)(信强作主题演讲)(郭磊作主题演讲)(戴康作主题演讲)8月30日,中国社科院学部委员、国家金融与发展实验室理事长李扬,全国政协经济委员会副主任、国务院发展研究中心原副主任刘世锦,中国社科院学部委员、世界经济与政治研究所研究员余永定,国家发改委宏观经济研究院原副院长马晓河,原南方科技大学商学院院长、讲席教授,原清华大学五道口金融学院副院长、紫光金融学讲席教授周皓,复旦大学美国研究中心副主任、台湾研究中心创始主任信强,广发证券首席经济学家郭磊博士,广发证券策略研究首席分析师戴康等嘉宾出席主旨论坛、海外论坛活动并作主题演讲,与现场嘉宾共享价值机遇及精彩纷呈的思辨之光。广发证券副总经理张威做开幕致辞。主旨论坛由广发证券发展研究中心总经理、电子首席分析师许兴军主持。百年未有变局 读懂中国新优势进入21世纪以来,世界也进入了百年未有之大变局时代。与过去不同的是,这一次世界变革,中国已经从被动顺势,转变为主要推动力量之一,呈现出新的发展格局和趋势。张威在开幕致辞中表示,本次论坛围绕海内外宏观政策、大类资产配置、双碳周期&能源革命、全球变局下的半导体产业、疫后消费复苏等重要话题,从三个方面重估中国优势,挖掘新的投资机遇:一要重估中国经济优势,在全球经济增长缺乏新引擎的背景下,对中国经济高品质发展前景进行定价;二要重估中国产业优势,乘势中国产业升级浪潮,对经济结构转型的优势赛道进行定价;三要重估中国企业优势,掘金中国新时代发展机遇下的优势企业,对资本市场优质上市公司定价。李扬表示,国内经济发展面临的压力依旧存在。未来宏观调控仍需加大力度,财政政策应当走向前台,货币政策则要“为稳定经济创造适宜的货币金融环境”。长期来看,仍然要坚持以改革开放为动力,致力于营造“让国企敢干、民企敢闯、外企敢投”的政策和制度环境,促进经济实现真正的高质量发展。刘世锦表示,投资方面除需关注基建以外,还有其他有关消费结构升级的服务业投资。从供给侧来看,需要继续激发结构性潜能,要关注“1+3+2”结构性潜能框架,即以都市圈城市群的发展为龙头,补上基础产业效率不高、中等收入群体规模不大、基础研发能力不强这三大短板;以及通过数字经济和绿色发展赋能。全球环境复杂 发展需要新思路今年以来,外部地缘政治风险和全球通胀压力加大,内部疫情扰动导致局部经济受影响,对国内发展带来前所未有挑战,也为改革发展提出新的要求。余永定指出,2022年第三季度至2023年,美国和全球的经济形势不容乐观。美国经济增速大概率会持续走低,欧洲不能排除陷入滞涨的可能性,日本经济不会有明显变化,发展中国家经济则可能加速分化。尽管外部环境恶化,中国经济在很大程度上能够隔离来自外部的不利冲击。在当前形势下,为了稳定增长,中国可以适度容忍杠杆率的提高,必要时要容忍一定程度的通胀。只要坚持“两个循环、内循环为主”的战略方针,坚持执行扩张性财政政策和货币政策,在国内外重重困难的包围下,中国经济依然能够实现“突围”并取得较好实绩。马晓河认为,我国经济面临的压力主要表现在两个方面。一是在需求侧,表现为两降一升,即投资增长率不断下降,消费增长严重收缩,甚至出现连续负增长;二是在供给侧,表现为一稳两放缓,即农业稳,夏粮丰收,农产品供给丰裕,但制造业和服务业增长率连续下滑,两大产业出现了明显负增长。其中,既有短期因素,由国内外重大事件导致的供给冲击和需求冲击,更重要的是我国的结构性矛盾。结构性矛盾体现在需求端,就是投资与消费长期失衡,消费引领经济增长能力不足;在供给端,中低端制造业供给过剩,中高端制造业发展不足;在动力机制上,大规模复制创新难以支持经济增长再迈新台阶,但自主创新仍然不足。因此,改革与发展需要新的思路和对策。周皓表示,美欧升息对中国的影响比较中性或者不是太大,对中国资本市场的影响不是很大。中国经济现在的挑战,是在下半年如何实现更快增长。在疫情压力逐步缓和、防疫政策进一步精准化之后,中国经济的毛细血管将得到改善,经济增长出现反弹预期。信强认为,美国不断加剧的对华战略打压和围堵,与新冠疫情的蔓延以及俄乌冲突延续相叠加,不仅为全球战略格局的演变注入了巨大的不确定性,而且对中国的外交战略和安全环境产生了重要影响。随着美国对华战略定位、战略目标、战略思维和战略手段的变化,未来随着中美战略的博弈也将持续展开,进而对中美关系未来的发展和演变产生重大影响。修复预期 市场或迎新增长今年以来,面对复杂严峻的国际环境、多点散发的国内疫情,资本市场呈现震荡格局。周皓强调,中国是个大的内生性经济,疫情对经济的影响进一步减小之后,政府再做出正确的预期引导,市场主体的信心将得到极大的提振,其融资需求疲软的状况也将得到改善。郭磊博士在题为“阳关三叠:三个时间维度看当前宏观面”的主题演讲中指出,7月经济放缓导致宏观面预期被打破,8月高频数据已基本企稳,本轮经济放缓带给股债两端的影响可能已大致反映完毕,9月随疫情、气温等因素高点过去,以及政策继续升温,宏观预期预计会有所修复。疫情防控常态化期间消费的天花板效应决定GDP的上限。短期增长的天花板效应和政策的偏宽来“资产荒”逻辑。逻辑上未来有三种可能打破目前状态,一是海外衰退;二是消费上限打开;三是地产形成对冲。三条线索目前尚未有端倪出现。往中期看,GDP增长目标下,投资率重新打平将是一个关键线索。从2035年GDP翻番目标倒推,则GDP年均复合增长率要在4.7%左右,其中第一个五年需要在5%以上,对应固定资产投资要在5%左右,这需要基建的现代化基础设施体系、地产的新发展模式、制造业的产业基础高级化等框架的搭建。从长期看,名义增长是股债定价的定价锚。无论是股票还是债券,其长期中枢都呈现出符合名义GDP定价的有效性。戴康表示,全球大类资产三季度演绎“紧缩+衰退”共振,四季度“衰退交易”将逐渐占据主导,大类资产或呈现美债利率高位运行后下行,大宗商品震荡分化,美股受盈利拖累下行。A股大势研判演绎“此消彼长,水到渠成”。此消(美国衰退),彼长(中国复苏),大概率演绎“美国衰退得快+中国复苏得慢”,贴现率驱动A股震荡上行,成长占优。今年小盘占优具备走出中等级别行情的潜质,不过随着相对估值修复至均值、信用利差历史低位之后,应留意地产基建信用预期变化带来的短期切换。戴康建议行业配置布局“资产重估,中国优势”。从“资产重估”来看,一方面压制性政策转向边际宽松的地产链将迎来重估,如地产、消费建材和家电等,另一方面“供需缺口”支撑的资源品迎来估值体系重塑,如煤炭、有色小金属等。从“中国优势”来看,一方面中国的消费优势,将依托于疫后内需市场的复苏实现供需修复,如食品饮料、批零社服,另一方面中国的制造业优势,将继续享受全球份额的提升及产业链的创新升级,如风电零部件、光伏组件、智能汽车;主题投资关注能源安全和国企改革。对于港股后续走势,戴康指出,当前美国存量流动性极度充裕,美联储加息周期,基本面改善亦能驱动港股上行。中美经济周期错位,中期港股上行趋势更为确定,待年底中国经济增长预期回升和美联储收紧放缓均兑现,为港股趋势上行提供积极催化剂。行业配置上关注“兼顾反转与确定性”三条主线,一是具有确定性的高股息策略;二是趋势反转,如供需梗阻进一步疏通的地产,疫后修复的餐饮供应链、啤酒,国潮的黄金珠宝、体育、化妆品,以及政策反转的平台经济、创新药等;三是追随景气,如具有中国制造优势的新能源车等。除主旨论坛和海外论坛外,广发证券还精心筹画了14场产业分论坛,交流内容覆盖新能源产业链、半导体国产替代、消费复苏与品牌崛起、消费医疗、大类资产配置等市场关心热点,邀请约500家优质上市公司做闭门交流,共论产业发展趋势和投资机遇,推动产业与资本之间的高效沟通,发掘未来投资机遇。 Copyright 2022 亚太商讯. All rights reserved. (via SEAPRWire)
More
Thrupenny Launches Yield Farming Platform SeaPRwire

Thrupenny Launches Yield Farming Platform

Thrupenny, an exciting crypto start-up, reached a major milestone, successfully launching a ground-breaking Yield Farming Platform. Singapore, September 06, 2022 – (SEAPRWire) – Thrupenny announces it has successfully launched its Thrupenny Yield Farming Platform dedicated to users that want to participate in DeFi yield-bearing opportunities. Yield farming is a strategy in which an investor deposits cryptocurrencies into a lending protocol in return for interests generated from transaction fees. As an added incentive, additional rewards from the ecosystem’s governance token are distributed to users. The platform aims to simplify the yield farming process by creating a seamless and streamlined process for users, removing any barriers to entry for the average investor to earn passive income that were earlier available to only a select few. Activity on the platform is expected to grow steadily in the coming months as its community users begin to use the services on offer. “We are extremely excited to launch the Thrupenny Yield Farming platform to allow DeFi investors access to a stable long-term yield generated from real-world assets,” says Nicholas Chau, CFO of Thrupenny. “The Thrupenny Yield Farming platform presents an excellent opportunity for users to lock their crypto holdings in a liquidity pool to earn attractive APY in a safe, sustainable and robust manner, and early users get to receive a higher APR, since the APR rates depend on the liquidity locked in a pool.” About Thrupenny Thrupenny, being a powerful DeFi platform, aims to be a one-stop solution for crypto holders to invest their cryptocurrencies in a decentralised manner. Thrupenny makes participation in a complicated area of crypto simple and accessible for all, giving users the control and insights from a single application. Through the Thrupenny platform, users can stake their crypto and start earning passive income with a click of a button. The platform is secured by an in-house team of security specialists and audited by industry-leading crypto auditing firms. The Thrupenny development team combined has decades of experience developing effective products that can shape the future and seeks to build a decentralized ecosystem incorporating numerous DeFi products and services which will drive a new direction of growth and feasibility in the cryptocurrency world. With the Thrupenny native token TPY, investors can enter a rich ecosystem that offers attractive APYs and much more. Media Contact Brand: Thrupenny Contact: Adrian Lee Email: cs@thrupenny.io Website: https://thrupenny.io/ SOURCE: Thrupenny The article is provided by a third-party content provider. SEAPRWire ( https://www.seaprwire.com/ ) makes no warranties or representations in connection therewith. Any questions, please contact cs/at/SEAPRWire.com Sectors: Top Story, Daily News SEA PRWire: PR distribution in Southeast Asia (Hong Kong: AsiaExcite, EastMud; AsiaEase; Singapore: SEAChronicle, VOASG; NetDace; Thailand: SEAsiabiz, AccessTH; Indonesia: SEATribune, DailyBerita; Philippines: SEATickers, PHNotes; Malaysia: SEANewswire, KULPR; Vietnam: SEANewsDesk, PostVN)
More
Scalable Solutions Introduces New Program, Helping Customers Perfect Their Trading Platforms SeaPRwire

Scalable Solutions Introduces New Program, Helping Customers Perfect Their Trading Platforms

Scalable Solutions reveals their approach to customer success management, its impact on the success of cryptocurrency exchanges working with them and what sets them apart as a white-label technology company. New York, NY, September 06, 2022 – (SEAPRWire) – Scalable Solutions is proud to announce the launch of their latest program which will help customers perfect their trading platforms. Scalable Solutions is a one-stop-shop for trading platforms looking to succeed. But what does success mean in the cryptocurrency exchange market? The answer can range depending on whom one asks, but generally speaking, success looks like having a satisfied user base that is ready to recommend the exchange as a reliable trading platform that is secure, resilient to attacks, user-friendly and provides trading opportunities to all its users, whether beginners or professional traders. Scalable Solutions offers its B2B customers the chance at a successful trading platform not only through its leading technology, but also through the technical and business support it provides via the Scalable customer success team. Scalable’s customer success team is there for their customers every step of the way, from implementation to launch and beyond. They are the ones who know the ins-and-outs of the customers’ trading platform, what the customer wants to achieve and the experience they want to provide their users with. There are three main points that Scalable Solutions has revealed as setting their customer experience apart from other white label exchange providers: 1. Scalable Solutions treats their customers as partners. Despite complicated enterprise processes, dedicated account managers are happy to face customers and engage in real conversations; the account managers accompany and support the customer from the very beginning. They strive for a long term relationship with their customers, becoming partners in the true sense of the word. Tim, Head of Customer Success at Scalable Solutions, shares,”Whenever we receive a customer request, we always dig deeper and find the best possible solution specifically for the customers’ needs. So while our technology might be white-label, our customer success approach is very individualistic.” 2. Scalable customers are welcome to discuss any business opportunity and search for mutually beneficial implementation options. Scalable has formed partnerships and implemented technological integrations based on customer needs and requests. This means that besides the readily available integration options that customers can use, if there are better suited options for the customers’ needs, the Scalable team will secure them. Furthermore, even the most sensitive topics can be directly discussed with the dedicated account managers. At the end of the day, people do business with people. “The fintech industry is no stranger to regulatory hurdles, and given that we serve clients all over the world, a wide spectrum of issues can arise. We’ve had situations where our customers faced challenges due to a force majeure; we patiently collaborated to restructure the way we work and accommodate the situations that arose in a mutually beneficial way. Situations like these have only made our partnership stronger,” says Tim. 3. Scalable Solutions‘ goal is the success and development of their customers. That is why there is practically no fixed framework for their interaction. While the process of working together is clear, the approach is individual to each customer to suit their needs. Their Customer Success team is distributed across different time-zones, ensuring they can be in touch whenever the customer needs it. “One of the ways we ensure our customers receive the right solutions for them is by actively listening to them, as well as by testing various solutions – when a customer is not sure of the exact solution they are after, we don’t throw the whole spectrum of services we offer right at them. Instead, we gradually introduce different integrations and specific wants and needs, continuously questioning and testing along the way to ensure the customer arrives at their desired results.” Ultimately, the Scalable Solutions customer success team is there for those who want to implement solutions that will take their exchange to the next level, and as a result, make their end-users happier trading with them. Thus, customer success is business success any way one looks at it. To discover more about the Scalable Solutions team and how they can help exchange businesses achieve a successful trading platform, get in touch with their team here. Follow Scalable Solutions on social media: Linkedin: https://www.linkedin.com/company/scalable-solutions-ag/ Telegram: https://t.me/scalable_insights Twitter: https://twitter.com/Scalable_AG Medium: https://scalablesolutions.medium.com/ Media Contact Brand: Scalable Solutions Contact: Media team Email: pr@scalablesolutions.io Website: https://scalablesolutions.io/ SOURCE: Scalable Solutions The article is provided by a third-party content provider. SEAPRWire ( https://www.seaprwire.com/ ) makes no warranties or representations in connection therewith. Any questions, please contact cs/at/SEAPRWire.com Sectors: Top Story, Daily News SEA PRWire: PR distribution in Southeast Asia (Hong Kong: AsiaExcite, EastMud; AsiaEase; Singapore: SEAChronicle, VOASG; NetDace; Thailand: SEAsiabiz, AccessTH; Indonesia: SEATribune, DailyBerita; Philippines: SEATickers, PHNotes; Malaysia: SEANewswire, KULPR; Vietnam: SEANewsDesk, PostVN)
More

巴西出口投资促进局与阿里巴巴签署谅解备忘录

HONG KONG, Sep 6, 2022 - (亚太商讯 via SEAPRWire.com) - 巴西出口投资促进局(ApexBrasil)于2022年9月3日的中国国际服务贸易会期间,与阿里巴巴集团就跨境电商平台的深化合作举行谅解备忘录签字仪式。双方在合作谅解备忘录的框架下扩大合作,加强巴西企业对电子商务、跨境贸易和数字化转型的了解,加速深化数字化跨境贸易,进一步通过电子商务为巴西产品出口到亚洲和全球市场创造更多机会。在合作谅解备忘录的框架下,阿里巴巴国际站上开设“巴西制造(Made in Brazil)”专属国家馆,当中将结合平台热销行业以及巴西制造的本地特色,筛选出当地100家有电商经验的企业,由ApexBrasil提供补贴,获得扶持入驻的机会。阿里巴巴国际站则提供运营方面的专属服务,以及定制化巴西出口的B2B分销服务。此外,为助力巴西培养数字经济人才,支援和培育当地电子商务生态的发展,ApexBrasil与阿里巴巴达成意向,将在巴西共同推进数字经济培训项目,旨在提高巴西企业家、专业人士和学生群体在数字经贸等领域的相关能力,为未来行业发展奠定稳固基础。2021年巴西电商销售增长35%,其中巴西商家通过阿里巴巴旗下电商平台在中国的销售额达到2.53亿美元,食品类尤为受中国消费者青睐。ApexBrasil与阿里巴巴建立了密切合作,除了共同助力巴西企业销往全球外,亦借此提升巴西商家对中国市场的了解和认识中国市场的机会,深化其与阿里巴巴旗下零售渠道的合作。在ApexBrasil持续帮助巴西中小企业加速数字化和国际化的支持下,巴西企业对于进驻阿里巴巴旗下电商平台充满热情,自2021年起,ApexBrasil通过“电商平台加速项目”触及到370家巴西企业对于使用阿里巴巴国际站销售产品感兴趣。ApexBrasil与阿里巴巴过往的持续合作催化了丰硕成果,今年6月开始,巴西商家与阿里巴巴进一步开启了一般贸易进口合作项目,成功促成2家重点商家合作意向,包括巴西精品咖啡SANTA MONIKA,巴西知名果汁品牌NATRUAL ONE,两家意向合同签批预计9月份完成,10月份将实现首单下达,并与阿里巴巴集团的线上线下分销平台共同合作,释放巴西优质商品在中国市场的潜力。巴西出口投资促进局业务总监Lucas Fiuza表示:“ApexBrasil一直致力于促进国际电子商务的发展,帮助巴西企业通过国际电子商务实现出口。值此之际,我想重点强调与阿里巴巴国际站现已启动的合作项目,巴西企业可以通过使用这一国际电商平台出口商品。我希望向关注我们的公司传达一个讯息:巴西是您发展业务的绝佳之地,巴西出口投资促进局是帮您寻找商机的最佳伙伴。广阔天地,机遇巴西。” Copyright 2022 亚太商讯. All rights reserved. (via SEAPRWire)
More

ApexBrasil Agency and Alibaba Signed a Memorandum of Understanding

HONG KONG, Sep 6, 2022 - (ACN Newswire via SEAPRWire.com) - The Brazilian Export and Investment Promotion Agency (ApexBrasil) held a memorandum of understanding (MoU) signing ceremony with Alibaba Group to deepen their cooperation on cross-border e-commerce platforms during the China International Fair for Trade in Services on September 3, 2022. Under the framework of the MoU, the two parties will expand cooperation and strengthen Brazilian enterprises' e-commerce, cross-border trade and digitalization, thus accelerating the deepening of digital cross-border trade, and creating more opportunities for Brazilian products to be exported to Asian and global markets through e-commerce.Under the framework of the MoU, the "Made in Brazil" national pavilion will be launched on Alibaba's international website. 100 local companies with e-commerce experience in the platform's hottest-selling industries will join "Made in Brazil" label, many of them receiving settlement support and subsidies from ApexBrasil. Alibaba.com provides exclusive services for operations as well as B2B distribution services for customized Brazilian exports. In addition, in order to cultivate Brazil's digital economy talents and support the development of the local e-commerce ecosystem, ApexBrasil and Alibaba agreed to jointly promote a digital economy training program in Brazil to educate Brazilian entrepreneurs as well as professionals and students in digital trade and relevant fields and provide a solid foundation for the industry's future development.In 2021, Brazil's e-commerce sales increased by 35%. Brazilian companies' sales in China through Alibaba's e-commerce platform are projected to reach US$ 253 million, with food products particularly in high demand by Chinese consumers. ApexBrasil has established close cooperation with Alibaba. In addition to promoting Brazilian companies' global sales, ApexBrasil is also taking this opportunity to enhance Brazilian companies' understanding of the Chinese market and its opportunities, hence deepening their cooperation with Alibaba's retail channels. With continuous support, ApexBrasil is accelerating the digitalization and globalization of Brazilian SMEs and Brazilian companies are enthusiastic about joining Alibaba's e-commerce platforms. Since 2021, ApexBrasil has reached 370 Brazilian companies interested in selling through Alibaba.com with the Acceleration program in Digital Platforms.The expanding cooperation between ApexBrasil and Alibaba over the years has carried out fruitful results. Since June this year, Brazilian companies and Alibaba successfully promoted the intention of 2 key companies to export their products to China, Brazilian specialty coffee SANTA MONIKA, a well-known Brazilian brand, and the juice brand NATURAL ONE. The signing and approval of the two contracts are expected to be completed in September with the first order placed in October. They will cooperate with Alibaba Group's hybrid (online and offline) platform to introduce Brazil's high-quality products to the Chinese market.Lucas Fiuza, Business Director of ApexBrasil said: "ApexBrasil has been working diligently to promote international e-commerce so that Brazilian companies can expand their export options to include e-commerce. Specifically, I would like to highlight the successful projects we have started with Alibaba.com so that more Brazilian companies can learn how to use this international platform for selling their products. I would also like to send a special message to all companies who are following us. Brazil is the right place for your business, and ApexBrasil is how you find the best deals. Think Big, Think Brazil." Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More
Value Research Center (VRC) publishes August White Paper: The VRC Value Model & EFRAG ACN Newswire

Value Research Center (VRC) publishes August White Paper: The VRC Value Model & EFRAG

KYOTO, Japan, Sep 6, 2022 - (ACN Newswire via SEAPRWire.com) - Companies and sustainability teams need a new model for measuring and managing stakeholder impacts, as claims of corporate greenwashing and value washing increase daily. The Value Research Center (VRC) at Doshisha University in Kyoto, Japan has announced the publication of its 2022 August White Paper, focusing on the European Financial Reporting Advisory Group (EFRAG's) latest disclosure drafts for sustainability reporting, and how this model aligns with and deepens the overall quality of the VRC Value Model.The Value Research Center (VRC) publishes 2022 August White Paper: The Value Model & EFRAGAccording to Professor Philip Sugai, Director of the Value Research Center, "After integrating EFRAG's 114 draft disclosure requirements into the VRC Value Model, we were impressed with the scope of EFRAG's coverage of many of the Value Model's stakeholders, themes and goals. Especially with their push for companies to document their impacts using 'double materiality', we see a shift towards greater understanding of business decisions on individual stakeholder groups."SAP Japan International Ambassador Paul Beddie said, "The VRC In Kyoto has been working to organize the world's top ESG and Sustainability Reporting frameworks into a goal-based, value creation model that will help companies to create value across their key stakeholders. Companies around the world are in desperate need of a way to consolidate the alphabet soup of standards to reduce their workload on ESG reporting and focus more on the critical ESG outcomes they transformed their businesses to achieve. "The VRC's Value Model is a very effective tool for doing just that. The additional integration of the draft reporting standards from EFRAG should also help companies doing business in the EU to align their disclosures with the EU Taxonomy."With the publication of the August White Paper, the VRC will begin to collaborate with several of the world's leading companies in adopting the VRC Value Model, applying it to their own ESG and sustainability reporting requirements, and creating forward-looking sustainability strategies rather than backwards-focused disclosures.Professor Sugai will be hosting a session at the UNGA77 Science Summit, where he will discuss the VRC Value Model and its broader practical applications, together with a panel of experts from academia, government, and business.The UNGA77 Science Summit session, "Valuing Value: How any Organization Can Measure Stakeholder Value and "Ethical Capitalism" (https://ssunga77.sched.com/event/1AWkD), will be held on Sept 26 from 9:00 to 11:30 AM EST. Registration for the complete UNGA77 Science Summit is free and available at https://ssunga77.sched.com/tickets.The "2022 August White Paper: The Value Model & EFRAG" is available for download at the Value Research Center website: www.valueresearchcenter.com/publications.For more information about the Value Research Center and its projects, please visit: www.valueresearchcenter.com, or email Professor Philip Sugai at: info@valueresearchcenter.com .About the Value Research CenterThe Value Research Center (VRC) at Doshisha University in Kyoto, Japan was established in November 2021. Its mission: to develop a practical system for organizations to measure, monitor, assess and report on the impacts that they have on various stakeholder groups.The VRC continues to enhance its Value Model, integrating new frameworks as they're introduced, bringing greater transparency, objectivity and measurability to value creation - in ways we didn't see. The VRC Value Model gives government and industry eyes to see the impacts they're actually having, to fix what's broken, and enhance what they're doing well. For more information, visit www.valueresearchcenter.com. Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More
Blackbixon Cafe Officially Debuts in Downtown KL ACN Newswire

Blackbixon Cafe Officially Debuts in Downtown KL

KUALA LUMPUR, Sep 6, 2022 - (ACN Newswire via SEAPRWire.com) - BlackBixon2Go Sdn. Bhd. (BB2GO), a subsidiary of Ni Hsin Group Berhad, is delighted to announce the official launch of the first BlackBixon Cafe & Restaurant today in a tastefully designed 3-storey bungalow house with a roof top garden.Mr. Khoo Chee Kong, Managing Director of BlackBixon2Go Sdn. Bhd.; Yang Berhormat Senator Dato' Sri Ti Lian Ker, Deputy Minister of Youth & Sports, Malaysia; Chermaine Poo, Independent Non-Executive Director of Ni Shin Group Berhad.; Dato' Minarwan Bin Datuk Haji Nawawi, Hockey Icon; Amarjeet Singh, General Manager of Marketing of BlackBixon2Go Sdn. Bhd. [L-R]The tastefully furnished cafe and restaurant with BlackBixon-themed wall graffiti and art pieces, is located along a tree-lined street on Jalan Inai, off Jalan Tun Razak, filled with old bungalows interspersed with offices. The Cafe has a total area of 5,993 sq. ft. occupying two floors and can accommodate up to 200 pax while the roof top garden opens up to a spectacular view of the Kuala Lumpur skyline.The Cafe caters to families as well as office workers looking for nourishing and tasty Western classics such as freshly prepared breads and pastries to a wide selection of hearty and delicious breakfast, lunch and dinner favourites accompanied by specialty coffees and must-try BlackBixon signature drinks. BlackBixon specialty coffees are brewed from premium arabica beans specially selected from the best plantations in Rwanda and Brazil.The official launch was attended by Yang Berhormat Senator Dato' Sri Ti Lian Ker, Deputy Minister of Youth & Sports, Malaysia.Mr. Khoo Chee Kong, Managing Director of BB2GO, said, "Following years of planning, the BlackBixon Cafe & Restaurant is a culmination of a dream that started with the distribution of healthy coffee beverages - energy, nutritional and original variants - under our concept of cafe@home @office @anywhere bringing to our customers the convenience of enjoying a cup of healthy coffee anywhere and everywhere. Not satisfied with providing the convenience to our customers to brew their own coffee, we took a further step to serve them fresh hot coffee at convenient locations around town. That's where our BB2GO barista bikers shine, serving coffee from our BB Coffee Bikes, which are electric bikes (EV Bikes) whose battery power is also used to operate the coffee machines. This makes our EV Bikes a totally self-sufficient mobile coffee bar that is green and environmentally sustainable.""The specialty dishes and signature drinks are created by our own chefs and baristas. Among the dishes are Charcoal Bun Beef Burger, Lamb Schnitzel, Chili Soft Shell Crab Pasta and Black Truffle Squid Ink Carbonara, while specialty drinks include Charcoal Latte and the Monochrome. We will have more savoury dishes and drinks to come as we set up other outlets in the Klang Valley and across the country.""We also take this opportunity to introduce our BlackBixon Sporting Hall of Fame where we honour the sports icons of Malaysia for their outstanding achievements and contributions to our country. In conjunction with the Grand Opening of our BlackBixon Cafe & Restaurant we are also inducting some of our great sporting icons into our BlackBixon Sporting Hall of Fame. They are Datuk Santokh Singh, Dato' Minarwan Bin Datuk Haji Nawawi, Karamjit Singh, M. Kumaresan, Muhammad Roslin Hashim and Muhammad Hafiz Hashim.""To qualify as a member of the BlackBixon Hall of Fame, nominees must have been selected to represent Malaysia as an Olympian, World Champion, retired from active sports and have contributed to the development of the sports at a senior level within a sport recognised by the Youth & Sports Ministry."Opening hours for BlackBixon Cafe & Restaurant are from 08.00 a.m. to 10.00 p.m., 7 days a week. BlackBixon Cafe & Restaurant serves only halal meats.Ni Hsin Group Berhad: NIHSIN [Bursa: 7215] [RIC: NHSN:KL] [BB: NHR:MK], http://www.ni-hsin.com/ Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More
Avance Clinical 宣布收购北美 CRO扩大生物技术的后期服务 ACN Newswire

Avance Clinical 宣布收购北美 CRO扩大生物技术的后期服务

SYDNEY, AU, Sep 6, 2022 - (亚太商讯 via SEAPRWire.com) - 澳大利亚生物技术 CRO 公司 Avance Clinical 已通过收购 CRO 合作伙伴公司 C3 Research Associates 扩展到北美,以使生物技术客户能够从早期研究到后期研究的无缝旅程。 Avance Clinical 的全球扩张计划得到了私募股权集团 Riverside Company 的支持。观看视频 https://www.avancecro.com/avance-clinical-north-america-operations/Avance Clinical 是澳大利亚和新西兰最大和最成熟的全方位服务 CRO,在 FDA 和所有其他主要监管机构的数据接受方面有着良好的记录。Avance Clinical 澳大利亚、新西兰和北美的联合运营为生物技术公司提供了独特的 GlobalReady 药物开发模式。Avance Clinical 的首席执行官 Yvonne Lungershausen 说:“近年来,Avance Clinical 一直与 C3 Research Associates 合作,他们有着相似的文化,并专注于客户服务和临床卓越。这种牢固的关系使 C3 Research Associates 成为 Avance Clinical 向北美扩张计划的自然收购选择。尽职调查过程耗时 6 个多月,我们很高兴现在欢迎我们的美国团队为我们的客户提供 GlobalReady 模型。此次收购使我们在澳大利亚和新西兰进行早期研究的生物技术客户可以无缝进入美国,继续他们的临床开发计划,保留相同的高质量 CRO,从而减少时间和成本,并提供 FDA 接受的高质量数据。这种 GlobalReady 模型旨在扩大生物技术公司的投资,使他们能够以更少的支出实现更大的临床开发里程碑,所有这些都以 FDA 接受的数据为保证。此外,在澳大利亚,43.5% 的临床支出回扣极具吸引力,为我们的客户提供了利用我们北美运营专业知识和团队的机会,同时保持在澳大利亚的服务以最大限度地发挥回扣潜力。我们经常指出,目前有超过 280 项全球 III 期试验在澳大利亚进行了 I 期研究,这再次证明了澳大利亚数据在 FDA 和其他主要监管机构中的可接受性。我们将对我们的美国业务进行重大投资,包括将团队扩大到 120 多人,并利用他们在广泛的治疗领域(特别是肿瘤学)的深厚行业经验。客户可以放心,世界一流的最佳实践技术、系统和流程将被整合到所有地区。”这种无缝的 GlobalReady 之旅旨在取得成功,生物技术公司可以:- 利用澳大利亚早期临床试验环境(没有IND 和 43.5% 的退税)- 为后期过渡或扩展到北美 - 无需更改 CRO(保留研究知识和流程/团队)- 在两个地区无缝实施全球剂量递增和剂量扩展试验- 利用显着的速度和成本优势- 确保数据质量——可转移且易于被 FDA 和其他监管机构接受Avance Clinical 团队提供卓越的研究批准和成功率,这可归功于其深厚的科学专业知识、先进的数据技术、对澳大利亚、新西兰和北美监管环境的了解,以及与网站和 KOL 的广泛关系。同时,Avance Clinical也是一家被澳大利亚基因科技监管办公室(OGTR)认证的基因科技CRO,这使其有资格进行疫苗以及基因修饰生物体相关的临床研究。我们有着非常高的回头业务率,这足以证明我们的技术以及以客户为本的临床专家可以在快节奏和强竞争的环境中脱颖而出,满足我们客户的需求。Avance Clinical在过去两年连续被Frost & Sullivan评为“CRO最佳实践奖 ”。了解澳大利亚临床试验优势: https://www.avancecro.com/the-australian-advantage/在这里与北美领导团队会面: https://www.avancecro.com/avance-clinical-north-america-operations/了解更多Avance Clinical执行临床试验的优势: https://www.avancecro.com/contact-us/关于Avance ClinicalAvance Clinical是澳大利亚和新西兰地区最大的一站式CRO公司。我们为客户提供高质量的临床研究服务以及符合国际标准的临床研究数据。我们的客户主要是处于早期研发阶段的生物科技公司,他们需要快捷灵活的临床研究服务。Frost & Sullivan奖Avance Clinical作为一家具有24年历史的CRO公司在过去两年连续被评为Frost & Sullivan亚太地区市场领袖 。临床前到临床一期和二期Avance Clinical经验丰富的ClinicReady团队可提供精准的临床前服务。澳大利亚政府的研发税务补助政策,让我们可以更经济,精准并灵活的帮助客户完成临床一期和二期的项目。客户有机会享受43.5%的政府现金补助,同时快速的监管审批政策使其能更早更快的开展临床研究。我们的解决方案以及客户为本,灵活多变,经手的临床研究覆盖超过110个适应症。我们的数据质量被国际监管机构广泛认可,包括美国FDA以及欧洲EMA。技术我们使用的系统多元化并且功能丰富,有最高效的以及客户所信任的执行力。Medidata、Oracle、IBM Watson和Medrio都是我们的系统长期供应商。媒体联系方式:Avance ClinicalChris Thompsonmedia@avancecro.com Copyright 2022 亚太商讯. All rights reserved. (via SEAPRWire)
More

智能专病机器人与数字医疗联合研发中心亮相服贸会 麦迪卫康(2159.HK)驶上智慧医疗新赛道

EQS 新闻 via SEAPRWire.com / 2022-09-06 / 11:59 UTC+8 智能专病机器人与数字医疗联合研发中心亮相服贸会 麦迪卫康(2159.HK)驶上智慧医疗新赛道 2022年9月1日,中国国际服务贸易交易会(「服贸会」)健康卫生服务专题展在首钢园展区拉开帷幕。首都医科大学附属北京天坛医院携手麦迪卫康(2159.HK)旗下北京麦迪卫康医疗科技有限公司和北京智煜健康科技有限公司、以及苏州玖物智慧科技有限公司(「玖物智慧」)以共建「智慧专病机器人与数字医疗联合研发中心」(「联合研发中心」)项目亮相服贸会。 随着全球新科技革命和产业变革深入发展,医疗数字化在近年来已经成为全球大趋势。自 2015 年开始,中国先后发布了《国务院关于积极推进“互联网+”行动的指导意见》、《“健康中国 2030”规划纲要》、《国家卫生健康委办公厅关于印发医院智慧服务分级评估标准体系(试行)的通知》等重要文件,支持数字医疗的稳步发展。2020年,国家卫生健康委印发了《关于进一步完善预约诊疗制度加强智慧医院建设的通知》,指导各地和各医院在创新建设完善智能医院系统。总结医院信息化建设实践,充分发挥信息技术在现代医院建设管理中的重要作用,通过智能服务、电子病历、智能管理等领域的建设,构建医疗、服务、管理「三位一体」的智能医院系统,为患者提供更高质量、更高效率、更加安全、更加体贴的医疗服务。这不但为医疗系统进一步数字化赋能,亦为拥有卓越数字化医疗服务及技术的平台创造巨大机遇。 首都医科大学附属北京天坛医院是一所以神经科学集群为特色,集医、教、研、防为一体的三级甲等综合医院,是亚洲神经外科临床、科研、教学基地。国家医学中心(辅导类单位)、国家神经疾病医学中心、国家神经系统疾病临床医学研究中心、国家神经系统疾病医疗质量控制中心、国家医师资格考试实践技能考试基地、全国脑血管病防治办公室、WHO神经科学培训合作中心等机构均设在医院。而在北京市委市政府印发的《北京市“十四五”时期国际科技创新中心建设规划》部署指导,以及国家医学中心的框架规划下,北京天坛医院设计规划了「联合研发中心」项目,融合社会力量共享共建跨学科、跨领域的研发平台,通过协调各方力量,建设国际医疗科技创新中心。 作为数字医疗技术平台的先行者,麦迪卫康凭借其20多年在慢病管理领域的丰富经验和资源,已成为国内领先的心脑血管疾病综合医疗营销解决方案提供商。此次,麦迪卫康将以创新的互联网医疗服务和数字医疗技术加入战略合作,打造智慧医疗平台与服务体系,融合智能机器人和垂直医疗领域的领先技术,推动数字医疗和智能专病机器人在临床应用的转化与落地,也为麦迪卫康在智慧医疗的拓展注入新的活力。麦迪卫康旗下的智煜健康,是一家专注于创新数字智能医疗的医疗科技企业,通过这次战略合作也将聚焦于数字疗法产品的开发,研发可独立应用也可与智慧硬件如机器人相结合的卒中专病领域的数字疗法产品。 玖物智慧则是全球领先的智慧移动机器人、轻型协作机械臂和激光传感器的研发、生产、销售及服务的高科技创新企业。玖物智能将以创新性研发为目标,为智能专病机器人的使用创建标准模式与可行技术,通过研发迭代逐步实现成熟的,可供多种临床场景使用的医用智能机器人。 展望未来,通过智能专病机器人与数字疗法研发中心的实践及试点,将逐步把全面的智慧专病机器人与数字疗法技术推广到二级以上医院广泛使用,助力智能医院、智能病房的建设,并建立相关的临床应用指南和评估标准。 文件: 智能专病机器人与数字医疗联合研发中心亮相服贸会 麦迪卫康(2159.HK)驶上智慧医疗新赛道 2022-09-06 此财经新闻稿由EQS Group via SEAPRWire.com转载。本公告内容由发行人全权负责。原文链接: http://www.todayir.com/sc/index.php
More
Eisai Presents New Data From its Oncology Portfolio and Pipeline at ESMO Congress 2022 JCN Newswire

Eisai Presents New Data From its Oncology Portfolio and Pipeline at ESMO Congress 2022

TOKYO, Sep 6, 2022 - (JCN Newswire via SEAPRWire.com) - Eisai Co., Ltd. announced today the presentation of research across various types of cancer from its oncology portfolio and pipeline during the European Society for Medical Oncology (ESMO) Congress 2022, which is taking place virtually and in-person in Paris, France from September 9 to 13. A late-breaking oral presentation of detailed results from the LEAP (LEnvatinib And Pembrolizumab) clinical program including the final analysis of the Phase 3 LEAP-002 trial will be featured in a Proffered Paper session (NCT03713593; Presentation: #LBA34). The study evaluated the combination of lenvatinib plus anti-PD-1 antibody pembrolizumab from Merck & Co., Inc., Rahway, NJ, USA versus lenvatinib monotherapy as a first-line treatment for patients with unresectable hepatocellular carcinoma. Additionally, two mini-oral presentations will feature updated efficacy and safety data from the pivotal Phase 3 CLEAR (Study 307)/KEYNOTE-581 trial evaluating the combination in patients with advanced renal cell carcinoma (NCT02811861; Presentation: #1449MO) and Phase 3 Study 309/KEYNOTE-775 trial evaluating the combination in patients with advanced endometrial carcinoma (NCT03517449; Presentation: #525MO). In addition, a new post-hoc analysis of three pivotal Phase 3 studies (Study 301/NCT00337103, Study 304/NCT02225470 and the EMBRACE trial/Study 305/NCT00388726) evaluating the efficacy of eribulin (HALAVEN) versus other chemotherapies (capecitabine, vinorelbine and Treatment of Physician's Choice [TPC], respectively) in patients living with metastatic breast cancer whose tumors have low or no HER2-expression will be presented during a poster session (Presentation: #259P). "We look forward to presenting data at ESMO, showcasing Eisai's latest research on both lenvatinib and eribulin, with the goal of continuing to help people living with various types of cancer," said Dr. Takashi Owa, Chief Scientific Officer, Deep Human Biology Learning, Senior Vice President, Eisai Co., Ltd. "Presentations on the LEAP clinical program as well as new analyses for eribulin reinforce our commitment to the ongoing research of our portfolio in an effort to better serve patients and healthcare providers." In March 2018, Eisai and Merck & Co., Inc., Rahway, NJ, USA (known as MSD outside the United States and Canada), through an affiliate, entered into a strategic collaboration for the worldwide co-development and co-commercialization of lenvatinib, both as monotherapy and in combination with pembrolizumab. To date, more than 15 trials have been initiated under the LEAP clinical program, which is evaluating the combination across multiple tumor types. This release discusses investigational compounds and investigational uses for FDA-approved products. It is not intended to convey conclusions about efficacy and safety. There is no guarantee that any investigational compounds or investigational uses of FDA-approved products will successfully complete clinical development or gain FDA approval.For more information, visit www.eisai.com/news/2022/news202265.html. Copyright 2022 JCN Newswire. All rights reserved. (via SEAPRWire)
More
Avance Clinical Announces North American CRO Acquisition to Expand Later Phase Services for Biotechs ACN Newswire

Avance Clinical Announces North American CRO Acquisition to Expand Later Phase Services for Biotechs

SYDNEY, AU, Sep 6, 2022 - (ACN Newswire via SEAPRWire.com) - Avance Clinical, the Australian CRO for biotechs, has expanded into North America with the acquisition of CRO partner company C3 Research Associates, enabling biotech clients a seamless journey from early phase to later phase studies. Avance Clinical has backing from private equity group Riverside Company for their global expansion program.Watch the video here: https://www.avancecro.com/avance-clinical-north-america-operations/Avance Clinical is the largest and most established full-service Australian and New Zealand CRO with a proven track-record of data acceptance by the FDA and all other major regulatory bodies.The combined Avance Clinical Australia, New Zealand, and North American operations deliver a unique GlobalReady drug development model for biotechs.Avance Clinical's CEO Yvonne Lungershausen said: "Avance Clinical has been working with C3 Research Associates in recent years and they share a similar culture and focus on customer service and clinical excellence. This strong relationship made C3 Research Associates a natural acquisition choice for Avance Clinical's expansion plans into North America. The due diligence process has taken more than 6 months and we are excited to now welcome our US team and offer the GlobalReady model for our clients. "This acquisition gives our biotech clients conducting their early phase studies in Australia and New Zealand a seamless journey into the US to continue their clinical development programs, retaining the same high-quality CRO, which reduces time and cost and delivers quality FDA-accepted data. This GlobalReady model is designed to extend biotechs' investments so they can achieve greater clinical development milestones with reduced spend, all with the assurance of FDA accepted data. "In addition, the attractive 43.5% rebate on clinical spend in Australia, offers our clients the opportunity to utilize our North American operations expertise and team, whilst maintaining services in Australia to maximise their rebate potential. "We often point to the fact that there are currently more than 280 Phase III global trials that have conducted their Phase I study in Australia, which again demonstrates Australian data acceptability with the FDA and other major regulatory authorities."We will be making significant investments in our US operations including growing the team to more than 120 people and leveraging their deep industry experience across a broad range of therapeutic areas, in particular oncology.Clients can be assured the world-class best practice technologies, systems and processes will be integrated across all regions."This seamless GlobalReady journey is designed for success whereby biotechs can:- Take advantage of the Australian early phase clinical trial landscape (No IND and 43.5% tax rebate)- Transition or expand into North America for later phases - without changing CROs (retain study knowledge and processes/team)- Seamlessly operationalise global dose-escalation and dose-expansion trials across the two regions- Harness significant speed and cost advantages- Be assured of quality data - transferable and readily acceptable by the FDA and other regulatory authorities The Avance Clinical team offers exceptional study approval and success rates which can be attributed to its deep scientific expertise, advanced data technologies, knowledge of the Australian, New Zealand and North American regulatory environment, and its extensive relationships with sites and KOLs.The company is also accredited as a gene technology CRO under the Office of the Gene Technology Regulator (OGTR) which allows it to manage pre-clinical and clinical trials for vaccines and GMO therapies.Avance Clinical's has achieved high growth and industry-leading repeat business rates with its focus on gold standard technology paired with solution-orientated clinical experts. This is the mix that biopharma clients clearly require in this fast-moving, competitive and high-stakes sector.Avance Clinical has been recognised for the past two consecutive years with the prestigious Frost & Sullivan CRO Best Practices Award.Learn about the Australian Advantage here: https://www.avancecro.com/the-australian-advantage/Meet the North American leadership team here: https://www.avancecro.com/avance-clinical-north-america-operations/For more information about the benefits of running your next study with Avance Clinical contact us https://www.avancecro.com/contact-us/About Avance ClinicalAvance Clinical is the largest premium full-service Australian CRO with operations across Australia, New Zealand and North America delivering quality clinical trials with globally accepted data for international biotechs. The company's clients are biotechs in their early phases of drug development that need fast, agile, and adaptive solution-oriented clinical research services.Frost & Sullivan AwardsAvance Clinical, a Frost & Sullivan Asia-Pacific CRO Market Leadership Award recipient for the past two years, has been providing CRO services in the region for 24 years.Pre-clinical to Later Phase Avance Clinical offers pre-clinical services with their experienced ClinicReady team right through to later phase clinical services leveraging significant Government incentive rebates of up to 43.5% and rapid start-up regulatory processes. With experience across more than 110 indications, the CRO can deliver world-class results and high-quality internationally accepted data for FDA and EMA review.State-of-the-art TechnologyAvance Clinical uses state-of-the-art technology and gold standard systems across all functional areas to provide clients with the most effective processes. Medidata, Oracle, IBM and Medrio are just some of the technology partners.Media Contacts: Avance ClinicalChris Thompsonmedia@avancecro.com Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More
Mitsubishi Power’s State-of-the-Art M701JAC Gas Turbine Exceeds 8,000 Actual Operating Hours JCN Newswire

Mitsubishi Power’s State-of-the-Art M701JAC Gas Turbine Exceeds 8,000 Actual Operating Hours

TOKYO, Sep 6, 2022 - (JCN Newswire via SEAPRWire.com) - Mitsubishi Power, a power solutions brand of Mitsubishi Heavy Industries, Ltd. (MHI), has achieved an accumulated 8,000 hours of actual operating hours (AOH) for its M701JAC gas turbine. The subject gas turbine unit was installed for gas turbine combined cycle (GTCC) power generation system operated as part of a joint venture between Thailand's Gulf Energy Development Public Company Limited, one of the country's largest independent power producers (IPP), and Mitsui & Co., Ltd. The 60Hz model M501JAC gas turbine previously achieved 8,000 AOH in June 2018, and with the 50Hz model M701JAC now having exceeded 8,000 AOH as well, the state-of-the-art air-cooled JAC (J Series Air Cooled) series has established an industry benchmark of reliability for both the 50Hz and 60Hz markets.JAC Advanced Class Gas TurbineFurther, a M501JAC model gas turbine utilized for a long-term demonstration operation begun in July 2020 at the T-Point 2 combined cycle power plant validation facility on the grounds of the Takasago Machinery Works in Hyogo Prefecture, has recently reproduced the result of more than 8,000 AOH. This achievement provides even more solid evidence of the reliability of JAC Series gas turbines.The GTCC power plant project in Thailand is a joint venture between Gulf Energy Development Public Company Limited and Mitsui & Co., Ltd. to build and operate two large-scale power plants, one in Chonburi Province and one in Rayong Province, comprising eight M701JAC gas turbine units with a combined total output of 5,300 megawatts (MW). The first of these units to be delivered, which has now exceeded 8,000 AOH, commenced operations at the end of March 2021 the Chonburi Province plant, approximately 130 kilometer southeast of the capital city of Bangkok. This power station already has three M701JAC units in operation.T-Point 2 is a state-of-the-art GTCC power generation validation facility including an M501JAC unit for 60Hz power generation and high-efficiency steam turbine, with total output of 566 MW. The facility conducts total plant optimization and verification in an actual grid-connected power plant to provide the technological backing for long-term, reliable operation. The long-term demonstration operation at T-Point 2 is managed by the Takasago TOMONI HUB Analytics and Performance Center, and incorporates many existing and newly developed digital applications included in the TOMONI Suite of Intelligent Solutions that make T-Point 2 the world's smartest power plant. Recently validated TOMONI solutions include AI-based applications to autonomously optimize plant performance and operation as well as reliability assurance applications using advanced status visualization, historical trending, and predictive diagnostics. T-Point 2 is also a core facility for the Takasago Hydrogen Park currently under construction, and will be utilized for operational validation using hydrogen fuel and integration of emerging technologies for total energy management, including hydrogen fuel utilization, hydrogen production and energy storage.Toshiyuki Hashi, MHI Senior Executive Fellow and Head of Energy Transition & Power Headquarters of Energy Systems, said regarding the achievement of this record, "We are extremely proud that the JAC Series gas turbines at these two plants have achieved both high reliability and efficiency, reaching 8,000 hours of operation. We believe that JAC Series gas turbines, which are able to stably provide clean energy with high efficiency through the use of hydrogen fuel, will play an important future role in realizing a carbon neutral society."JAC Series gas turbines utilize a high turbine inlet temperature of 1,650 degrees C, providing a world-leading power generating efficiency of 64%, the highest level for a power plant. Since the commercial launch of the J Series gas turbines (which includes the JAC Series) in 2009, orders have steadily increased from customers in Japan and around the world, reaching a cumulative total of 92 units. Of these, 52 units are currently in commercial operation, with aggregate operating hours exceeding 1.7 million hours for the J Series as a whole.Mitsubishi Power, building on this establishment of an industry benchmark of reliability with 8,000 AOH for both the M701JAC and M501JAC models, will further focus its efforts on promoting the widespread adoption of state-of-the-art JAC Series gas turbines, and contribute to lessening environmental loads amid a backdrop of securing the stable power generation that is essential to global economic development, and energy transition strategies.About MHI GroupMitsubishi Heavy Industries (MHI) Group is one of the world's leading industrial groups, spanning energy, smart infrastructure, industrial machinery, aerospace and defense. MHI Group combines cutting-edge technology with deep experience to deliver innovative, integrated solutions that help to realize a carbon neutral world, improve the quality of life and ensure a safer world. For more information, please visit www.mhi.com or follow our insights and stories on spectra.mhi.com. Copyright 2022 JCN Newswire. All rights reserved. (via SEAPRWire)
More
Leading tech professionals to virtually discuss cloud solutions and sustainable data centres in Qatar ACN Newswire

Leading tech professionals to virtually discuss cloud solutions and sustainable data centres in Qatar

QATAR, UAE, Sept 3, 2022 - (ACN Newswire via SEAPRWire.com) - The potential of the cloud and sustainable data centres is still far from being realised, as a consequence, Trescon's World Cloud Show is looking to help Qatar in its mission to enhance digital transformation. As the Official Cloud Sponsor of the World Cloud Show - Qatar, Oracle is set to provide a major push to this agenda.The event that is virtually taking place on September 6, 2022, will focus on the Qatari market, and will feature exciting keynotes, government and enterprise use-case presentations, product showcase, panel discussions and tech talks to discuss the latest challenges and explore the latest applications of cloud-based solutions."The combination of AI technologies and the IoT infrastructure within a data processing framework that integrates edge and cloud computing is key to the delivery of energy management platforms capable of addressing the complexities of hybrid power systems," said Dr. Antonio Sanfilippo, Chief Scientist and Program Director at Qatar Foundation/Qatar Environment & Energy Research Institute.Manish Khanijo, Manager – Technology & Security at Qatar Free Zone Authority stated, "Pandemic has accelerated digital and cloud adoption many folds. It is time that we accept data security in a borderless perimeter. With faster provisioning and limitless scalability, organizations can now focus on delivering more value to their customers and stakeholders. Easier access to data and omnipresent services require organizations to implement more advanced technology in improving data visibility and protection.""Cloud computing is vital to support businesses towards a digital transformation sustainable ecosystem", was quoted by Thuraya Al-harthi, Senior Specialist - Innovation & Emerging Technology Development, Ministry of Transport, Communication and Information Technology, Muscat Governorate, Oman.Ahmed Zewail, Group IT Director, Wadi Group said, "Digital transformation is not only using the computer and internet for an efficient and effective value creation process; but, it refers to the changes that new technology has on everything; on how we think, plan, operate, communicate, interact, and configure. The digital transformation has an obvious, lasting, and continuous impact, not only on the enterprises and economics, but a larger scale on our lives and our society as well.""Cloud computing allows organizations to scale, maintain flexibility, and focus their efforts on business operations. The World Cloud Show in Qatar is a fantastic effort toward getting the local market ready to embrace cloud computing and learn about its benefits," stated Hamid Ali Raja, Senior Audit Manager, GWC Logistics, Qatar.World Cloud Show – Qatar will feature renowned thought leaders and early adopters of tech as speakers, including but not limited to:John Mankarios - Vice President, QInvest LLC, Qatar,Manish Khanijo - Manager - Technology & Security, Qatar Free Zone Authority, QatarE. Belal Hafnawi - Commissioner - Board Member, Telecommunications Regulatory Commission (TRC-Jordan), JordanAbdullah Faisal Biary - Chief Information Security Officer, United Cooperative Assurance, Saudi ArabiaAnthony Samir - Head of Cybersecurity Unit, Ministry of Health and Population – Egypt, EgyptGigi Mathew Thomas - Group Head - IT & Digital Transformation, Ittihad International Investment LLC, United Arab EmiratesYaniv Naor - Director of Data Governance & Management, Knauf, GermanyImran Chowdhury - Global Head of Data Protection and Governance, Al Jazeera Media Network, QatarKarthik Ananda Rao - Regional Technical Head, ManageEngine, MEA, UAEDany Gemayel - Senior Director – Business Applications, Oracle, Upper GulfAws Hattab - Sr.Director of Contact Center, Bank Al Etihad, JordanThuraya Al-harthi - Senior Specialist - Innovation & Emerging Technology Development, MTCIT, OmanMohamed Ghazala - Head of Data Architecture & Analytics, Leading Bank in Egypt, EgyptMai Alowaish - Chief Data & Innovation Officer, Gulf Bank of Kuwait, KuwaitAhmad Musa - Head of Planning and a DBA candidate, University of Strathclyde, UAEAhmed Zewail – Group IT Director, Wadi Group, Egypt; to name a few.CEO of Trescon, Mithun Shetty quoted, "We're happy and looking forward to hosting a yet another, exciting and insightful edition of this global series. We hope it'll be a fruitful engagement for all our attendees."The gathering will take place on the online meeting platform Vmeets to facilitate networking and commercial dealings in a vibrant and lifelike virtual environment. Aside from networking with solution providers in virtual exposition booths, private consulting rooms, and private networking rooms, attendees can interact with speakers in Q&A sessions.The event will have insightful sessions, technology use cases, panel discussions, private consultations, and networking rooms.The 12th global edition of World Cloud Show - Qatar is officially sponsored byOfficial Cloud Partner - Oracle;Gold Sponsor - GBI & Prime HoldingSilver Sponsors - Cerebrum & Manage Engine.To confirm interest in attending, visit - World Cloud Show Qatar.About World Cloud ShowWorld Cloud Show is a thought-leadership-driven, business-focused, global series of events that takes place in strategic locations/time zones across the world.The Qatar edition is gathering pre-qualified CIOs, CEOs, CTOs, Heads of Research, Industry Practitioners, IT Decision Makers and Experts in Cloud Computing among others from cross-industry verticals across the region.About TresconTrescon is a global business events and consulting firm that provide a wide range of business services to a diversified client base that includes corporations, governments, and individuals. Trescon is specialized in producing highly focused B2B events that connect businesses with opportunities through conferences, roadshows, expos, demand generation, investor connect, and consulting services.For further details about the announcement, please contact:Nupur Aswani, Head – PR, Media & Corporate Communications,Trescon+919555915156 | media@tresconglobal.com Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More
Novotech参加2022年ESMO大会 – 新数据显示亚太地区的肿瘤学试验增长100% ACN Newswire

Novotech参加2022年ESMO大会 – 新数据显示亚太地区的肿瘤学试验增长100%

SYDNEY, Sep 6, 2022 - (亚太商讯 via SEAPRWire.com) - 亚太地区领先的生物技术临床研究机构 Novotech 将参加 2022 年 ESMO 大会,新数据显示亚太地区的肿瘤学试验在 2017 年至 2021 年期间实现了 100% 的增长,并为全球免疫肿瘤学临床开发的三分之一以上做出了贡献药物。Novotech 在亚太地区和美国拥有丰富的临床研究机构运营经验,为早期至晚期生物技术临床研究提供独特且无与伦比的服务套件。GlobalData 为 Novoteoch 编制的临床数据还发现:“到 2021 年底,40% 的主动免疫肿瘤临床试验至少涉及亚太地区的一个地点,其中大部分试验在中国进行,其次是澳大利亚、韩国、日本和台湾。在亚太地区,2017-2021 年间,肿瘤学试验的比例翻了一番。在中国,肿瘤学试验的增长与癌症发病率的显着增加、国内公司开发创新产品、专注于免疫肿瘤学以及细胞治疗的领先地位有关。”在此处下载报告:免疫肿瘤学 – 亚太地区 – 临床试验概况https://novotech-cro.com/whitepapers/immuno-oncology-asia-pacific-clinical-trial-landscape与美国和欧盟5国相比,亚太地区临床试验的演变https://novotech-cro.com/whitepapers/evolution-clinical-trials-asia-pacific-region-compared-us-and-eu5据 Novotech 全球临床服务副总裁 Yooni Kim 所说:“亚太地区以其庞大的患者群体、竞争力较弱的临床试验环境和世界级的 KOL 为加快临床试验提供了一个令人信服的解决方案,此外,监管改革加快了审批流程。Novotech 的服务交付模式是根据生物技术客户的需求量身定制的。我们的本地团队拥有卓越的现场和研究人员访问权限,我们的项目管理方法强调解决问题、所有权和灵活性,我们对数据和技术的投资确保客户能够实时访问试验绩效。此外,亚太地区和美国经验丰富的 CRO 业务为早期至晚期生物技术临床研究提供了一套独特且无与伦比的服务。”Novotech 最近被评为全球领先的 CRO 中的前 10 名 CRO,并在过去 3 年中签署了 45 份领先的网站合作协议。关于Novotech健康控股Novotech健康控股有限公司(“Novotech”)是亚太地区及美国领先的生物技术专家 CRO。 Novotech 是一家 CRO,拥有综合实验室和 I 期设施,提供药物开发咨询和临床开发服务。它有助于在所有试验阶段和广泛的治疗领域成功进行大约 4,000 项临床试验。Novotech具有明显优势,可以为在亚洲及美国进行临床试验的生物制药客户提供服务。详细信息请访问 https://novotech-cro.com/contact媒体联系人David JamesE: communications@novotech-cro.com澳大利亚: +61 2 8218 2144美国: +1 415 951 3228亚洲: +65 3159 3427 Copyright 2022 亚太商讯. All rights reserved. (via SEAPRWire)
More
Dammam Valley/KSA to acquire the majority of Arcensus GmbH/Germany to accelerate the global implementation of Whole Genome Sequencing in genetic diagnostics and delivery of breakthrough technologies in genomic bioinformatics ACN Newswire

Dammam Valley/KSA to acquire the majority of Arcensus GmbH/Germany to accelerate the global implementation of Whole Genome Sequencing in genetic diagnostics and delivery of breakthrough technologies in genomic bioinformatics

ROSTOCK, Germany & DAMMAM, KSA, Sep 5, 2022 - (ACN Newswire via SEAPRWire.com) - Dammam Valley in partnership with other investment partners, announce to acquire a majority stake in Arcensus GmbH/Germany. Arcensus, founded by Dr. Arndt Rolfs, a multi-entrepreneur in biotechnology, CEO and founder of several innovative biotech companies, is a digital health and diagnostics company providing comprehensive genomic diagnostic services based on Whole Genome Sequencing.With a cross-functional, international team of geneticists, medical experts and data scientists, Arcensus, one of the world's most innovative genetic biotechnology companies, offers its knowledge and bioinformatic expertise in genomic interpretation together with cutting-edge medical and preventive health applications. The management of Arcensus is convinced that with the worldwide implementation of Whole Genome Sequencing as the first line of genomic testing, the genomic era will start quickly and will conquer the molecular medicine market in a short time.The initiative for the take-over comes from the Kingdom's aim to improve the global speed in implementing genomic testing for the early diagnosis of genetic diseases, mainly in cancer and rare genetic disorders. The financial investment led by Dammam Valley will allow Arcensus to speed up the penetration of the worldwide markets with its innovative solutions. It will be the backbone for developing a comprehensive multi-omic strategy.Dr. Abdulrahman Al-Olayan, CEO of Dammam Valley said, "This is an important step in our global healthcare strategy for KSA, as we believe that the early diagnosis and preventive testing based on real-life genomic expertise with Whole Genome Sequencing is a key ingredient to accelerate the development of, and access to, new future treatments. As a leading technology company in genomic testing, Arcensus GmbH, founded by the visionary multi-entrepreneur, Dr. Arndt Rolfs, is best positioned to provide a deep understanding of bioinformatic technologies and data analytics infrastructure needed not only for the Kingdom of Saudi Arabia but for medical research and development efforts across the globe. A key principle of this is to preserve Arcensus' autonomy. We are delighted that the founder of Arcensus, Dr. Arndt Rolfs, will continue to manage operations, sit on the board and remain a significant shareholder."Dr. Arndt Rolfs, Arcensus founder and CEO, said, "Dammam Valley will be a tremendous partner for the global expansion to us and shares our vision for building a worldwide healthcare platform in modern preventive medicine as well as early diagnostics of all genetic diseases. This important partnership will allow us to increase the investments in our modern technology and services platform, as well as our knowledge-based data extraction of the genomic data."Under the terms of the agreement, Dammam Valley along with other investors will make a double-digit million Euro payment on a fully diluted basis. The parties agree Arcensus to continue its current business model, a network of partnerships and overall objectives following the transaction's closing. The integrity of the proprietary patient data will be maintained, as will the dedicated sales, marketing, and life sciences business activities.About Dammam ValleyEstablished in 2021, Dammam Valley is a semi-government Investment company, solely owned by Imam Abdulrahman bin Faisal University, and with a raised capital of 100,000,000 SAR. It strives to be a source and destination for biotechnology innovation and healthcare in the Middle East and is the Nation's premier hub for evaluating and incubating biotech innovations. Aiming to stimulate investment, support projects, and forge quality partnerships in the fields of Health & Biotechnology, in addition to focusing on numerous other sustainable investments in various fields of interest.About ArcensusArcensus is a digital healthcare and diagnostics company that empowers people to take control of their health. The company provides the highest-standard, secure, trusted, and comprehensive diagnostic service based on Whole Genome Sequencing. Arcensus analyses the complete genetic information in human DNA and identifies the predispositions and reasons for unclear symptoms with the help of cutting-edge bioinformatic technology, including artificial intelligence. The interpretation of the genomic data suggests better treatment options and helps individuals take preventive measures to live a healthier and longer life.From our offices in New Jersey - United States, Rostock and Berlin - Germany, a cross-functional team of genetic experts, medical doctors, and data scientists works to make the most sophisticated and best genetic interpretation with medical and health prevention applications accessible to everyone. For more information, visit https://arcensus-diagnostics.com/.Important Notice and DisclaimerThis press release contains "forward-looking statements" within the meaning of the U.S. federal securities laws. Statements contained herein that are not clearly historical in nature are forward-looking, and the words "anticipate," "believe," "continues," "expect," "estimate," "intend," "project," and similar expressions and future or conditional verbs such as "will," "would," "should," "could," "might," "can," and "may," are generally intended to identify forward-looking statements. Such forward-looking statements involve known and unknown risks, uncertainties, and other important factors that may cause Arcensus' actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, negative worldwide economic conditions and ongoing instability and volatility in the worldwide financial markets, the effects of the COVID-19 pandemic on our business and results of operations, possible changes in current and proposed legislation, regulations and governmental policies, pressures from increasing competition and consolidation in our industry, the expense and uncertainty of regulatory approval, including from the U.S. Food and Drug Administration, our reliance on third parties and collaboration partners, including our ability to manage growth and enter into new client relationships, our dependency on the rare disease industry, our ability to manage international expansion, our reliance on key personnel, our reliance on intellectual property protection, fluctuations of our operating results due to the effect of exchange rates, our ability to streamline cash usage, our requirement for additional financing and our ability to continue as a going concern, or other factors.Contact information:Arcensus GmbHAhmad Malik Communication ManagerTel: +49 381 20267000 Email: Ahmad.malik@arcensus-diagnostics.com Dammam Valley Dalal AlsarawiCommunication ManagerTel: 013 333366Email: dalal.alsarawi@dammamvalley.sa www.dammamvalley.saThis press release is issued through EmailWire(TM) (www.emailwire.com) - the global newswire service that provides Press release distribution with guaranteed results. Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More
AsiaTop Announces Ambitious Global Expansion and Web3-Based Tradable Loyalty Programs SeaPRwire

AsiaTop Announces Ambitious Global Expansion and Web3-Based Tradable Loyalty Programs

Hong Kong, September 05, 2022 – (SEAPRWire) – AsiaTop Loyalty, one of the largest loyalty rewards solution companies in Hong Kong and the Greater Bay Area, after its USD 10 million fundraising round, AsiaTop Loyalty has announced a rapid market expansion plan across Asia Pacific and Europe, leveraging web 3.0 and Metaverse. With its headquarter incorporated in Hong Kong, and part of its market expansion plan across Asia Pacific and Europe, AsiaTop is planning to open a Singapore office and to further collaborate with its strategic investor in London after the recent USD 10 million fundraising round. Early this year, AsiaTop has successfully launched AsiaTop 2.0 App with an innovative loyalty-as-a-service model to merchants for their CRM and membership programme. With the newly launched AT Bird Metaverse, AsiaTop has developed a long-term strategy by leveraging the Web 3.0 ecosystem to foster the connectivity and new experiences for the engagements of customers and merchants. “Our customer base has reached over 1 million of active users, whilst well supported and served by over 50,000 merchants, positioning AsiaTop as an unicorn and the largest loyalty solution company in Hong Kong and the Greater Bay Area,” said Andy Chen, the CEO of AsiaTop Loyalty. He also added: “With our headquarter founded in Hong Kong (the city that ranked #1 Fintech Hub in Asia for 2021), we are also eyeing on other fast growing markets such as Southeast Asia countries, including Thailand, Philippines, Malaysia and Singapore. Riding on our strong strategic partnership with Syndicate Capital Group as well as other strategic investors, we are seriously considering exploring business opportunities and capital markets from London and other European countries. AsiaTop is entering into Web 3.0 ecosystem to increase our data driven customer engagement and to boost our revenue and marketing ROI. AT Brid Metaverse is one of our priority projects, which is probably the 1st ever tradable loyalty NFT in Hong Kong and Great Bay Area. We expect the AT Bird Metaverse will boost our ROI by up to 12x through gamified customer experience.” About AsiaTop AsiaTop Loyalty is a leading loyalty rewards solution provider with consumer app that will be shared by 70 million of population in the Greater Bay Area. It provides a convenient and affordable consumer coupon platform for hundreds of thousands of merchants and partners, including those in Hong Kong. AsiaTop was ranked first in the 2021 Deloitte Hong Kong Technology Fast & Rising Star Program. It was also the winner of IFTA Fintech Achievements Award. Social Links Linkedin: https://www.linkedin.com/company/asiatoployalty/ Facebook: https://www.facebook.com/at.reward/ Media Contacts Brand: Asiatop Loyalty Limited Contact: Andy Chen E-mail: andy.chen@asiatop.asia / info@asiatop.asia Website: https://en-asiatop.com/ SOURCE: Asiatop Loyalty Limited The article is provided by a third-party content provider. SEAPRWire ( https://www.seaprwire.com/ ) makes no warranties or representations in connection therewith. Any questions, please contact cs/at/SEAPRWire.com Sectors: Top Story, Daily News SEA PRWire: PR distribution in Southeast Asia (Hong Kong: AsiaExcite, EastMud; AsiaEase; Singapore: SEAChronicle, VOASG; NetDace; Thailand: SEAsiabiz, AccessTH; Indonesia: SEATribune, DailyBerita; Philippines: SEATickers, PHNotes; Malaysia: SEANewswire, KULPR; Vietnam: SEANewsDesk, PostVN)
More